qmpsb qmpsb qmpsb is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug. qmpsblegal statuslegal status ca: schedule ii de: npsg (industrial and scientific use only) uk: under psychoactive substances act identifiers iupac name 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate cas number312606-87-4pubchem cid3929482chemspider3151524unii55q8b94hs5chemblchembl245876chemical and physical dataformulac22h22n2o4smolar mass410.49 g·mol−13d model (jsmol)interactive image smiles cc1ccc(cc1(=o)(=o)n2ccccc2)c(=o)oc3cccc4cccnc34 inchi inchi=1s/c22h22n2o4s/c1-16-10-11-18(15-20(16)29(26,27)24-13-3-2-4-14-24)22(25)28-19-9-5-7-17-8-6-12-23-21(17)19/h5-12,15h,2-4,13-14h2,1h3key:worimyadzqjwou-uhfffaoysa-n qmpsb was first discovered by nathalie lambeng and colleagues in 2007. it acts as a full agonist of the cb1 receptor and cb2 receptor with ki values of 3 nm and 4 nm, respectively. many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive cb2 receptor. this work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004. the quinolin-8-yl ester motif of qmpsb led to the discovery of other designer cannabinoids such as pb-22 and bb-22.